TALVEY 2 mg/mL solution for injection

DRUG2 trials

Sponsors

Fundacion Pethema, Region Hovedstaden

Conditions

Haematological diseases; any disorder that primarily affects the bloodMultiple Myelomabone marrowthe lymphatic system and/or blood-forming organs.

Phase 2

An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab) in the frontline therapy of newly diagnosed high-risk multiple myeloma

Active, not recruitingCTIS2024-514016-26-00

Fundacion PethemaMultiple Myeloma

Start: 2023-06-22Target: 30Updated: 2025-05-07

Phase 4

A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematological diseases (BLOOD-dose): core protocol

Not yet recruitingCTIS2026-525658-13-00

Region Hovedstadenbone marrow, Haematological diseases; any disorder that primarily affects the blood, the lymphatic system and/or blood-forming organs.

Target: 200Updated: 2026-06-25